We have recently begun enrolling patients in a Phase 1 #ClinicalTrial with a new #oncology candidate. PTX-35 is an antibody that targets an entirely novel receptor involved in the immune response to #cancer. Learn more about the trial here: http://bit.ly/2VmX0kS